甲型、乙型、丙型和丁型流感病毒对巴洛沙韦的敏感性。
Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir.
出版信息
Emerg Infect Dis. 2019 Oct;25(10):1969-1972. doi: 10.3201/eid2510.190607. Epub 2019 Oct 17.
Abstract
Baloxavir showed broad-spectrum in vitro replication inhibition of 4 types of influenza viruses (90% effective concentration range 1.2-98.3 nmol/L); susceptibility pattern was influenza A ˃ B ˃ C ˃ D. This drug also inhibited influenza A viruses of avian and swine origin, including viruses that have pandemic potential and those resistant to neuraminidase inhibitors.
摘要
巴洛沙韦对 4 种类型的流感病毒具有广谱的体外复制抑制作用（90%有效浓度范围为 1.2-98.3nmol/L）；敏感性模式为 A 型流感病毒> B 型流感病毒> C 型流感病毒> D 型流感病毒。该药物还抑制了禽源和猪源的甲型流感病毒，包括具有大流行潜力和对神经氨酸酶抑制剂耐药的病毒。
相似文献
1
Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir.
Emerg Infect Dis. 2019 Oct;25(10):1969-1972. doi: 10.3201/eid2510.190607. Epub 2019 Oct 17.
2
Baloxavir marboxil: the new influenza drug on the market.
Curr Opin Virol. 2019 Apr;35:14-18. doi: 10.1016/j.coviro.2019.01.006. Epub 2019 Mar 8.
3
Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil.
Viruses. 2019 Nov 15;11(11):1066. doi: 10.3390/v11111066.
4
Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil.
Sci Rep. 2019 Mar 5;9(1):3466. doi: 10.1038/s41598-019-39683-4.
5
Baloxavir heralds a new era in influenza virus biology.
Respir Investig. 2019 Jan;57(1):1-2. doi: 10.1016/j.resinv.2018.10.002. Epub 2018 Nov 3.
6
Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility.
Proc Natl Acad Sci U S A. 2020 Apr 14;117(15):8593-8601. doi: 10.1073/pnas.1916825117. Epub 2020 Mar 26.
7
In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.
Antiviral Res. 2018 Dec;160:109-117. doi: 10.1016/j.antiviral.2018.10.008. Epub 2018 Oct 11.
8
Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models.
PLoS One. 2019 May 20;14(5):e0217307. doi: 10.1371/journal.pone.0217307. eCollection 2019.
9
Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018.
Antiviral Res. 2019 Apr;164:91-96. doi: 10.1016/j.antiviral.2019.02.007. Epub 2019 Feb 13.
10
The Synergistic Effect of Baloxavir and Neuraminidase Inhibitors against Influenza Viruses In Vitro.
Viruses. 2024 Sep 14;16(9):1467. doi: 10.3390/v16091467.
引用本文的文献
1
Design, synthesis and biological evaluation of a novel class of indazole-containing compounds with potent anti-influenza activities targeting the PA-PB1 interface.
Acta Pharm Sin B. 2025 Jun;15(6):3163-3180. doi: 10.1016/j.apsb.2025.04.014. Epub 2025 Apr 19.
2
PA and PA-X: two key proteins from segment 3 of the influenza viruses.
Front Cell Infect Microbiol. 2025 Mar 14;15:1560250. doi: 10.3389/fcimb.2025.1560250. eCollection 2025.
3
Antiviral Susceptibility of Influenza A(H5N1) Clade 2.3.2.1c and 2.3.4.4b Viruses from Humans, 2023-2024.
Emerg Infect Dis. 2025 Apr;31(4):751-760. doi: 10.3201/eid3104.241820. Epub 2024 Mar 10.
4
Antiviral Susceptibility of Swine-Origin Influenza A Viruses Isolated from Humans, United States.
Emerg Infect Dis. 2024 Nov;30(11):2303-2312. doi: 10.3201/eid3011.240892. Epub 2024 Oct 8.
5
Baloxavir Resistance Markers in Influenza A and B Viruses in the Americas.
Drug Healthc Patient Saf. 2024 Sep 14;16:105-113. doi: 10.2147/DHPS.S470868. eCollection 2024.
6
Monitoring Influenza C and D Viruses in Patients With Respiratory Diseases in Japan, January 2018 to March 2023.
Influenza Other Respir Viruses. 2024 Jun;18(6):e13345. doi: 10.1111/irv.13345.
7
Influenza C virus susceptibility to antivirals with different mechanisms of action.
Antimicrob Agents Chemother. 2024 May 2;68(5):e0172723. doi: 10.1128/aac.01727-23. Epub 2024 Apr 8.
8
The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir.
Arch Virol. 2024 Jan 12;169(2):29. doi: 10.1007/s00705-023-05958-5.
9
Generation and Characterization of an Influenza D Reporter Virus.
Viruses. 2023 Dec 16;15(12):2444. doi: 10.3390/v15122444.
10
Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses.
Viruses. 2023 Nov 16;15(11):2264. doi: 10.3390/v15112264.
本文引用的文献
1
Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil.
Sci Rep. 2019 Mar 5;9(1):3466. doi: 10.1038/s41598-019-39683-4.
2
Detection of Influenza C Virus Infection among Hospitalized Patients, Cameroon.
Emerg Infect Dis. 2019 Mar;25(3):607-609. doi: 10.3201/eid2503.181213.
3
Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018.
Antiviral Res. 2019 Apr;164:91-96. doi: 10.1016/j.antiviral.2019.02.007. Epub 2019 Feb 13.
4
Emerging Influenza D Virus Threat: What We Know so Far!
J Clin Med. 2019 Feb 5;8(2):192. doi: 10.3390/jcm8020192.
5
Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.
Euro Surveill. 2019 Jan;24(3). doi: 10.2807/1560-7917.ES.2019.24.3.1800666.
6
Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil.
Front Microbiol. 2018 Dec 6;9:3026. doi: 10.3389/fmicb.2018.03026. eCollection 2018.
7
In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.
Antiviral Res. 2018 Dec;160:109-117. doi: 10.1016/j.antiviral.2018.10.008. Epub 2018 Oct 11.
8
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
N Engl J Med. 2018 Sep 6;379(10):913-923. doi: 10.1056/NEJMoa1716197.
9
Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.
Sci Rep. 2018 Jun 25;8(1):9633. doi: 10.1038/s41598-018-27890-4.
10
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.
Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-463. doi: 10.2183/pjab.93.027.
Zotero 插件